ANTHEM · Syncode Bio · Personalized Cancer Immunity

Every tumor writes
its own signature.
ANTHEM writes
the cure to match.

Antigenic · Therapeutic · Human Engineered Medicines — patient-specific neoantigen vaccines that rewrite the story of cancer treatment.

Explore the Pipeline → Contact the Team
20M+
new cancer cases per year globally
~49%
lower recurrence-or-death with personalized mRNA + checkpoint
<6 wk
biopsy-to-vial target turnaround
scroll
The ANTHEM Pipeline

Blood + Biopsy →
Patient-Specific Vaccine

SAMPLE → DECODE → PREDICT → MANUFACTURE → DOSE

01 🧬
Sample
Tumor biopsy + matched blood. Outpatient collection, minimal disruption.
02 🔬
Decode
WES + RNA-seq, HLA typing, and variant calling at sequencing scale.
03 🧠
Predict
AI ranks neoantigens for HLA-I/II affinity, clonality, and immunogenicity.
04 ⚗️
Manufacture
GMP mRNA-LNP or long-peptide; 15–25 neoantigens per patient.
05 💉
Dose
IM injection ± anti-PD-1. Outpatient. Repeat boosters as needed.
ANTHEM vs Cell Therapy

Why a shot beats
a manufacturing odyssey

Outpatient administration. No lymphodepletion. Designed for solid tumors. A fraction of the cost.

ANTHEM Vaccine CAR-T / TIL
Administration Outpatient IM injection ICU-grade infusion
Lymphodepletion Not required Required, suppressive
CRS / ICANS risk Minimal High (boxed warnings)
Solid tumors Designed for them Limited efficacy
Cost of goods $ tens of thousands $ hundreds of thousands
Re-dosing Easy boosters Complex, often one shot
Competitive Moat

Where ANTHEM compounds
an unfair advantage

🤖
Proprietary AI Ranker
Multi-modal scoring: MHC-I/II binding, TCR recognition, clonality, expression. Trained on in-house immunopeptidomics data no competitor can replicate.
⚡
Dual Modality
mRNA-LNP for breadth; long peptides + adjuvant for fragile patients and cold-chain-limited markets. One platform, two delivery modes.
🏭
Closed-Loop GMP
Automated, parallelized N-of-1 manufacturing line. Per-patient run cost falls with every batch — a structural cost moat that widens over time.
🔒
Composition + Method IP
Patient-class composition claims, ranker methods, LNP formulation, and dosing regimens — a layered IP estate that protects every layer of the stack.

Science is de-risked

Neoantigen approach clinically validated across multiple tumor types

Melanoma NSCLC Pancreatic GBM MSS-CRC
Get in Touch

From every patient's tumor —
a vaccine only they could need.

Syncode Bio is building ANTHEM as the operating system for N-of-1 cancer immunity.

ANTHEM@syncode.bio
Request One-Pager Partnership Inquiry